Nikola Zagorec, Alizée Calamel, Margaux Delaporte, Eric Olinger, Sarah Orr, John A Sayer, Vignesh-Guru Pillay, Anne Sophie Denommé-Pichon, Frederic Tran Mau-Them, Sophie Nambot, Laurence Faivre, Elisabet Ars, Roser Torra, Albert Cm Ong, Olivier Devuyst, Noberto Perico, Aurore Michel Després, Hugo Lemoine, Jonathan de Fallois, Romain Brousse, Aurélie Hummel, Bertrand Knebelmann, Nathalie Maisonneuve, Jan Halbritter, Yannick Le Meur, Marie-Pierre Audrézet, Emilie Cornec-Le Gall
{"title":"Clinical Spectrum and Prognosis of Atypical Autosomal Dominant Polycystic Kidney Disease Caused by Monoallelic Pathogenic Variants of IFT140.","authors":"Nikola Zagorec, Alizée Calamel, Margaux Delaporte, Eric Olinger, Sarah Orr, John A Sayer, Vignesh-Guru Pillay, Anne Sophie Denommé-Pichon, Frederic Tran Mau-Them, Sophie Nambot, Laurence Faivre, Elisabet Ars, Roser Torra, Albert Cm Ong, Olivier Devuyst, Noberto Perico, Aurore Michel Després, Hugo Lemoine, Jonathan de Fallois, Romain Brousse, Aurélie Hummel, Bertrand Knebelmann, Nathalie Maisonneuve, Jan Halbritter, Yannick Le Meur, Marie-Pierre Audrézet, Emilie Cornec-Le Gall","doi":"10.1053/j.ajkd.2024.10.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale & objective: </strong>Monoallelic predicted Loss-of-Function (pLoF) variants in IFT140 have recently been associated with an autosomal dominant polycystic kidney disease (ADPKD)-like phenotype. This study sought to enhance the characterization of this phenotype.</p><p><strong>Study design: </strong>Case series.</p><p><strong>Setting & participants: </strong>Seventy-five among 2797 European individuals with ADPKD-like phenotypes who underwent genetic testing that revealed pLoF IFT140-variants.</p><p><strong>Findings: </strong>The 75 individuals (median age 56 years, 53.3% females) were from 61 families and were found to have 41 different monoallelic pLoF IFT140-variants. The majority of individuals presented with large, exophytic kidney cysts (median [range] total kidney volume 688 ml [201-4139]), and 90.2% were classified using the Mayo Imaging Classification as Mayo Class 2A. Arterial hypertension was present in 50.7% of the individuals (median [range] age at diagnosis 59 years [29-73]). Only one patient developed kidney failure (at age 69 years). A significant difference in age-adjusted eGFR between male and female patients was observed (P<0.001). 56.3% of the individuals over the age of 60 years had an eGFR less than 60ml/min/1.73m<sup>2</sup>. The estimated genetic prevalence of monoallelic pLoF IFT140 variants was 19.76 (95%CI=18.8-20.7) and 27.89 (95%CI=23.8-31.9) per 10,000 in the Genome Aggregation Database and the 100,000 Genomes Project (100kG), respectively. CyKD (ICD-10 Q61) was associated with pLoF IFT140 variants (P=2.9x10<sup>-9</sup>, OR=5.6 (3.3-9.2)) only in 100kG.</p><p><strong>Study limitations: </strong>Retrospective study; younger patients and patients with milder forms of IFT140-related CyKD may not be diagnosed.</p><p><strong>Conclusions: </strong>Individuals with monoallelic IFT140 pLoF variants are likely to develop kidney cysts atypical of classical ADPKD and generally have a favorable kidney prognosis.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.ajkd.2024.10.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale & objective: Monoallelic predicted Loss-of-Function (pLoF) variants in IFT140 have recently been associated with an autosomal dominant polycystic kidney disease (ADPKD)-like phenotype. This study sought to enhance the characterization of this phenotype.
Study design: Case series.
Setting & participants: Seventy-five among 2797 European individuals with ADPKD-like phenotypes who underwent genetic testing that revealed pLoF IFT140-variants.
Findings: The 75 individuals (median age 56 years, 53.3% females) were from 61 families and were found to have 41 different monoallelic pLoF IFT140-variants. The majority of individuals presented with large, exophytic kidney cysts (median [range] total kidney volume 688 ml [201-4139]), and 90.2% were classified using the Mayo Imaging Classification as Mayo Class 2A. Arterial hypertension was present in 50.7% of the individuals (median [range] age at diagnosis 59 years [29-73]). Only one patient developed kidney failure (at age 69 years). A significant difference in age-adjusted eGFR between male and female patients was observed (P<0.001). 56.3% of the individuals over the age of 60 years had an eGFR less than 60ml/min/1.73m2. The estimated genetic prevalence of monoallelic pLoF IFT140 variants was 19.76 (95%CI=18.8-20.7) and 27.89 (95%CI=23.8-31.9) per 10,000 in the Genome Aggregation Database and the 100,000 Genomes Project (100kG), respectively. CyKD (ICD-10 Q61) was associated with pLoF IFT140 variants (P=2.9x10-9, OR=5.6 (3.3-9.2)) only in 100kG.
Study limitations: Retrospective study; younger patients and patients with milder forms of IFT140-related CyKD may not be diagnosed.
Conclusions: Individuals with monoallelic IFT140 pLoF variants are likely to develop kidney cysts atypical of classical ADPKD and generally have a favorable kidney prognosis.
期刊介绍:
The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.